Jci_page_head_homepage_01 Jci_page_head_homepage_02
Dan Ma, Julian P.H. Shield, Wendy Dean, Isabelle Leclerc, Claude Knauf, Rémy Burcelin, Guy A. Rutter, Gavin Kelsey
Published in Volume 114, Issue 3
J Clin Invest. 2004; 114(3):339–348 doi:10.1172/JCI19876
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Structure and expression of human TNDM transgene. (A) Human PAC RP3-340H11 contains the entire ZAC and HYMAI genes. The nine exons of ZAC are indicated as bars above the line, the 2 exons of HYMAI below the line; arrows indicate the start sites for and direction of transcription. Restriction sites BsiWI or SfiI for linearization of the PAC for microinjection are indicated. Transmission and integrity of the PAC in transgenic mice was assessed by PCR using the markers indicated; transgene copy number was estimated using the probe indicated. (B) Scheme for the RT-PCR assay for simultaneous detection of human ZAC (h) and mouse Zac (m) mRNAs. RT-PCR products were digested with StyI, which specifically cleaves the human product. (C) RT-PCR of ZAC and Zac in RNA from neonatal tissues of line TNDM29 hemizygous mice after paternal transmission of the transgene. Control lanes are nontransgenic mouse brain RNA (mouse) and human fetal brain RNA (human). (D) RT-PCR of ZAC and Zac RNA in the adult tissues from line TNDM29 and TNDM35 hemizygotes after paternal transmission. (E) RT-PCR of human HYMAI in the neonatal tissues of TNDM29 hemizygotes. Amplification of ZAC RNA in the same cDNA samples was used as an amplification control.